About Us



Founded in 2019 and headquartered in San Diego, California, Entos is focused on disrupting therapeutic discovery with its cutting-edge platform that uses AI-driven automated synthesis to rapidly design small-molecule therapeutics. Driven by technology derived from Caltech and the University of Bristol, Entos' team is comprised of renowned scientists and engineers with world-class expertise in machine learning and software development, as well as computational and medicinal chemistry.

Executive Team

Tom Miller

CEO
12 years as Professor at Caltech. Quantum and machine learning methods.

Fred Manby

CTO
18 years as Professor at U Bristol. Quantum theory and software engineering.

Sarah Trice

COO
15 years Merck/Sigma-Aldrich, MIT Sloan MBA. Cheminformatics and automation.

Tim Cernak

CSO
9 years Merck; 3 years Professor at U Michigan. High-throughput synthesis and drug discovery.

Scientific Advisory Board

Frances Arnold

Nobel Prize in Chemistry. Linus Pauling Professor at Caltech. Member of President's Science and Tech Advisory Board and Alphabet Board of Directors.

Connor Coley

Assistant Professor of Chemical Engineering at Massachusetts Institute of Technology.

Derek Lowe

Director in Chemical Biology Therapeutics at Novartis, and author of In the Pipeline at Science Magazine.

Jack Taunton

Professor of Cellular Molecular Pharmacology at UCSF, co-founder of Cedilla, Principia Biopharma, GBT, Kezar.

Ken Brameld

Senior Advisor for Samsara Biocapital, and former SVP Head of Research, Principia Biopharma.

Collaborators

Anima Anandkumar

Bren Professor of Computing at Caltech.